Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Edegem – page 31

516 clinical trials in Edegem, Belgium across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Edegem at a glance
516
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

516 trials in Edegem

Open in trial search

Haematological malignancy+1

Not recruiting

Study of Elraglusib Alone or with Chemotherapy for Patients with Refractory Blood Cancers or Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Elraglusib
  • Sponsor:Actuate Therapeutics Limited

Acute myeloid leukaemia

Not recruiting

Study on WT1 mRNA DC Vaccine to Prevent Relapse in Adults with Acute Myeloid Leukemia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:WT1 mRNA DC
  • Sponsor:Antwerp University Hospital

Brain stem glioma+1

Not recruiting

Study of WT1 LAMP mRNA DC Immunotherapy for Children with High-Grade Glioma and Diffuse Intrinsic Pontine Glioma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:WT1 LAMP mRNA DC
  • Sponsor:Antwerp University Hospital

Neoplasm

Not recruiting

Study on WT1/IL15/IL15Ra mRNA DC Vaccine for Patients with Advanced or Refractory Solid Tumors of the Pancreas, Esophagus, Liver, or Ovaries

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Wt1/Il15/Il15Ra Mrna Dc
  • Sponsor:Antwerp University Hospital

Pleural mesothelioma malignant

Not recruiting

Study of WT1 LAMP mRNA DC Vaccine for Patients with Malignant Pleural Mesothelioma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:WT1 LAMP mRNA DC
  • Sponsor:Antwerp University Hospital

Glioblastoma

Not recruiting

Study on WT1 LAMP mRNA DC and Temozolomide for Patients with Newly Diagnosed Glioblastoma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:WT1 LAMP mRNA DC
  • Sponsor:Antwerp University Hospital

B precursor type acute leukaemia

Not recruiting

Study on Adding Blinatumomab to Treatment for Adults with Precursor B-Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Mucopolysaccharidosis II

Not recruiting

Study on the Effectiveness and Safety of DNL310 vs Idursulfase for Children and Young Adults with Mucopolysaccharidosis Type II

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Idursulfase
  • Sponsor:Denali Therapeutics Inc.

Atrial fibrillation+2

Not recruiting

Study on Long-Term Anticoagulation with Rivaroxaban vs. Acetylsalicylic Acid for Patients at Risk of Stroke After Atrial Fibrillation Ablation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:University Of Ottawa Heart Institute

Dermatitis atopic

Not recruiting

Study on Tralokinumab for Moderate-to-Severe Atopic Hand Eczema in Patients Needing Systemic Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tralokinumab
  • Sponsor:Leo Pharma A/S

Lung neoplasm malignant

Not recruiting

Study on Durvalumab and Domvanalimab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:AstraZeneca AB

Primary progressive multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Edegem

What the registry says about research in the country

01 Infectious Diseases & Immunology

Groundbreaking research focusing on viral infections and vaccine development, including studies for influenza, RSV, and COVID-19. Multiple trials are evaluating immune responses and vaccine efficacy in different age groups.

  • Vaccine Development
  • Immune Response Studies
  • Prevention Strategies

Special attention is given to vulnerable populations, including elderly adults and pregnant women.

02 Liver & Metabolic Disorders

Innovative studies addressing Primary Biliary Cholangitis and Hepatitis D treatments. Research includes evaluation of novel therapeutics and their impact on disease progression.

  • Liver Disease Management
  • Clinical Outcomes
  • Antiviral Therapies

Trials focus on improving patient outcomes and developing targeted treatments.

03 Oncology & Cancer Care

Advanced research in breast cancer and lung cancer treatments, exploring new therapeutic combinations and targeted approaches for better patient outcomes.

  • Metastatic Disease
  • Targeted Therapies
  • Treatment Innovation

Focus on personalized medicine approaches and innovative treatment combinations.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.